Real-Time Margin Measurement
for Precision Cancer Surgery
Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.
- Reduce early-stage cancer recurrence risk
- Conserve lung function
- Improve surgical workflow
- Shorten hospital length of stay
NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.
Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.
Navigation Sciences initiates clinical feasibility study of the NaviSci™ System. Read more
Navigation Sciences receives approval from MassGeneral Brigham IRB to begin first in human clinical trial of NaviSci System. Read more
Navigation Sciences completes oversubscribed, $2.4 million Series A financing. Read more
FDA clears Navigation Sciences IDE for first clinical trial. Read more
Navigation Sciences raises $1.5 million seed round. Read more
Navigation Sciences acquires exclusive rights to novel technology for minimally invasive lung cancer, and other soft tissue procedures. Read more
NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team